X
API Suppliers
0
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
0
0
0
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
https://www.globenewswire.com/news-release/2024/04/09/2860211/0/en/Nicox-2024-Ordinary-and-Extraordinary-Shareholder-Meeting.html
https://www.globenewswire.com/news-release/2024/04/02/2856272/0/en/Number-of-voting-rights-as-of-March-31-2024.html
https://www.globenewswire.com/news-release/2024/03/20/2849092/0/en/Results-from-Mont-Blanc-Phase-3-Trial-of-Nicox-s-NCX-470-in-Glaucoma-Published-in-the-American-Journal-of-Ophthalmology.html
https://www.globenewswire.com//news-release/2024/02/01/2822282/0/en/Number-of-votings-rights-as-of-January-31-2024.html
https://www.globenewswire.com//news-release/2023/12/01/2789431/0/en/Number-of-voting-rights-as-of-November-30-2023.html
https://www.globenewswire.com/news-release/2023/05/03/2660631/0/en/Number-of-voting-rights-as-of-April-30-2023.html
https://www.globenewswire.com/news-release/2023/04/26/2654638/0/en/New-Data-on-Two-Nicox-s-Assets-NCX-470-and-NCX-1728-Presented-at-ARVO-2023.html
https://www.globenewswire.com/news-release/2023/04/26/2654679/0/en/Transfer-of-Nicox-s-shares-to-Euronext-Growth-Paris-effective-on-April-28-2023.html
https://www.globenewswire.com/news-release/2023/04/19/2649683/0/en/Nicox-Provides-First-Quarter-2023-Financial-and-Business-Highlights.html
https://www.globenewswire.com/news-release/2023/03/01/2618514/0/en/Number-of-voting-rights-as-of-February-28-2023.html
https://www.globenewswire.com/news-release/2023/03/01/2617829/0/en/Nicox-Ordinary-Shareholder-Meeting-of-February-28-2023-Approval-of-all-Resolutions.html
https://www.globenewswire.com//news-release/2023/01/06/2584195/0/en/Nicox-Half-year-liquidity-contract-statement-with-Kepler-Cheuvreux.html
https://www.globenewswire.com//news-release/2023/01/03/2582362/0/en/Number-of-voting-rights-as-of-December-31-2022.html
https://eyewire.news/articles/nicoxs-partner-fera-pharmaceuticals-to-investigate-naproxcinod-as-potential-covid-19-adjuvant-treatment/?c4src=home:sidebar
https://globenewswire.com/news-release/2018/09/27/1576930/0/en/Nicox-and-Fera-Pharmaceuticals-to-Focus-on-a-Rare-Disease-Indication-for-Naproxcinod.html
Market Place
Share 
